









Markets
/
Stocks
/
nasdaq-lrmr
/

Larimar Therapeutics Inc

LRMR

4.280USD

+0.200+4.90%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

274.04MMarket Cap

LossP/E TTM



Larimar Therapeutics Inc

4.280

+0.200+4.90%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-17

Key Insights

The company's fundamentals are relatively weak. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. Despite a weak stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

50 / 507

Overall Ranking

151 / 4723

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 12 analysts

Strong Buy

Current Rating

19.636

Target Price

+390.91%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. It intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 127.98.

Overvalued

The company’s latest PE is -2.61, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 70.20M shares, decreasing 4.14% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 2.14M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.23.

Financial Health

Currency: USD Updated：2025-09-17

The company's current financial score is 5.45, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.45

Change



Financials

2.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.42

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-17

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -2.61, which is 2.45% below the recent high of -2.67 and -122.45% above the recent low of -5.80.

Score

Industry at a Glance

Previous score

2.00

Change

0.8

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 50/507

No Data

Earnings Forecast

Currency: USD Updated：2025-09-17

The company’s current earnings forecast score is 9.17, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Larimar Therapeutics Inc is 18.00, with a high of 40.00 and a low of 10.00.

Score

Industry at a Glance

Previous score

9.17

Change

Support & Resistance

No Data

Analyst Rating

Based on 12 analysts

Strong Buy

Current Rating

19.636

Target Price

+381.28%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Larimar Therapeutics Inc

LRMR

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-17

The company’s current price momentum score is 8.68, which is higher than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 4.40 and the support level at 3.63, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.59

Change

0.09

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(1)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

0.030

Buy

RSI(14)

62.117

Neutral

STOCH(KDJ)(9,3,3)

76.703

Buy

ATR(14)

0.274

Low Volatility

CCI(14)

174.536

Buy

Williams %R

1.429

Overbought

TRIX(12,20)

0.360

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

4.050

Buy

MA10

4.016

Buy

MA20

3.915

Buy

MA50

3.720

Buy

MA100

3.127

Buy

MA200

3.262

Buy

Institutional Confidence

Currency: USD Updated：2025-09-17

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 94.16%, representing a quarter-over-quarter decrease of 8.18%. The largest institutional shareholder is The Vanguard, holding a total of 2.14M shares, representing 2.50% of shares outstanding, with 27.17% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Deerfield Management Company, L.P.

21.23M

RA Capital Management, LP

6.05M

Blue Owl Capital Holdings LP

4.78M

+2.69%

Opaleye Management Inc.

3.95M

+106.49%

Millennium Management LLC

3.56M

+429.50%

BlackRock Institutional Trust Company, N.A.

2.84M

-4.65%

The Vanguard Group, Inc.

Star Investors

2.22M

+1.13%

Alyeska Investment Group, L.P.

1.44M

+46.58%

Two Sigma Investments, LP

788.77K

+416.17%

Citadel Advisors LLC

434.29K

Risk Assessment

Currency: USD Updated：2025-09-17

The company’s current risk assessment score is 3.01, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.03. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.